Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis

Experimental Cell Research
Michael RussellK Riabowol

Abstract

The INhibitor of Growth (ING) family of plant homeodomain (PHD) proteins induce apoptosis and regulate gene expression through stress-inducible binding of phospholipids with subsequent nuclear and nucleolar localization. Relocalization occurs concomitantly with interaction with a subset of nuclear proteins, including PCNA, p53 and several regulators of acetylation such as the p300/CBP and PCAF histone acetyltransferases (HATs), as well as the histone deacetylases HDAC1 and hSir2. These interactions alter the localized state of chromatin compaction, subsequently affecting the expression of subsets of genes, including those associated with the stress response (Hsp70), apoptosis (Bax, MDM2) and cell cycle regulation (p21WAF1, cyclin B) in a cell- and tissue-specific manner. The expression levels and subcellular localization of ING proteins are altered in a significant number of human cancer types, while the expression of ING isoforms changes during cellular aging, suggesting that ING proteins may play a role in linking cellular transformation and replicative senescence. The variety of functions attributed to ING proteins suggest that this tumor suppressor serves to link the disparate processes of cell cycle regulation, cell suicid...Continue Reading

References

Feb 13, 1997·Oncogene·Z Kelman
Jun 19, 1998·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·E Warbrick
Aug 11, 1998·Trends in Biochemical Sciences·Z Kelman, J Hurwitz
Oct 22, 1998·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·M H Kuo, C D Allis
Dec 5, 1998·Biochimica Et Biophysica Acta·T Tsurimoto
Mar 11, 1999·Cytogenetics and Cell Genetics·Y ShimadaM Horie
Sep 28, 1999·Oncogene·T ToyamaK Riabowol
Nov 30, 1999·American Journal of Hematology·M OhmoriJ Takahara
Nov 30, 1999·Frontiers in Bioscience : a Journal and Virtual Library·T Tsurimoto
Dec 22, 1999·Biochemical Pharmacology·M S SheikhA J Fornance
Nov 15, 2000·British Journal of Cancer·K J CheungG Li
Dec 22, 2000·Journal of Molecular Biology·J PascualP E Wright
Aug 2, 2001·Proceedings of the National Academy of Sciences of the United States of America·M NagashimaC C Harris
Oct 16, 2001·The Journal of Biological Chemistry·M J WagnerC C Helbing
Oct 30, 2001·International Journal of Radiation Biology·T PauneskuG E Woloschak
Jan 19, 2002·EMBO Reports·Catherine M Green, Geneviève Almouzni
Feb 9, 2002·American Journal of Hematology·K ItoM Kizaki
Mar 9, 2002·Molecular and Cellular Biology·Eric KalkhovenAlt Zantema
Apr 23, 2002·The British Journal of Dermatology·E I CamposG Li
May 17, 2002·The Journal of Biological Chemistry·Diego VieyraKarl Riabowol
Jun 11, 2002·Biochemical and Biophysical Research Communications·Seckho HaYunjaie Choi
Sep 24, 2002·Experimental Cell Research·K-John Cheung, Gang Li
Nov 26, 2002·Trends in Cell Biology·Xiaolan FengKarlT Riabowol

❮ Previous
Next ❯

Citations

Mar 8, 2013·Future Microbiology·Abhik Saha, Erle S Robertson
Nov 21, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Lin Qi, Yang Zhang
Oct 24, 2007·Molecular and Cellular Biology·Masayoshi IizukaM Mitchell Smith
Mar 13, 2008·The Journal of Biological Chemistry·Krishna P SarkerShirin Bonni
Apr 3, 2008·The Journal of Biological Chemistry·Alicia PalaciosFrancisco J Blanco
Sep 20, 2008·BMC Genomics·Paul M K GordonKarl Riabowol
Aug 15, 2009·PloS One·Julius Halaschek-WienerAngela R Brooks-Wilson
Mar 8, 2013·Cellular and Molecular Life Sciences : CMLS·Claudia Cosentino, Raul Mostoslavsky
Mar 14, 2007·Expert Reviews in Molecular Medicine·Stuart P Atkinson, W Nicol Keith
Mar 19, 2014·FEBS Letters·Gesche Tallen, Karl Riabowol
Jan 25, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Shuping YuanYongzhong Hou
Feb 26, 2013·Current Opinion in Cell Biology·Ramiro Iglesias-BartolomeJ Silvio Gutkind
Jun 9, 2012·Plant Physiology and Biochemistry : PPB·Catherine B DieckWendy F Boss
Nov 12, 2009·Ageing Research Reviews·Antero Salminen, Kai Kaarniranta
Oct 24, 2007·Trends in Biochemical Sciences·Mohamed A Soliman, Karl Riabowol
Jan 9, 2007·Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology·Caren C HelbingLouis J Guillette
Jan 22, 2009·The Plant Journal : for Cell and Molecular Biology·Woo Yong LeeChang Seob Kwon
May 30, 2009·The Journal of Pathology·Ming LiSong-bin Fu
Jul 19, 2008·International Journal of Cancer. Journal International Du Cancer·Damien YthierRémy Pedeux
Sep 18, 2008·International Journal of Cancer. Journal International Du Cancer·Haiming DingSteven M D'Ambrosio
Apr 20, 2016·Frontiers in Microbiology·Shaoni BhattacharjeeAbhik Saha
Apr 16, 2013·PloS One·Lisa YuDonald J Fujita
Aug 22, 2016·Journal of Cancer Research and Clinical Oncology·Runyun ZhangYongzhong Hou
Dec 7, 2011·Molecular and Cellular Biology·Nikita AvvakumovJacques Côté
Oct 26, 2018·Pflügers Archiv : European journal of physiology·Tian-Tian ZhuPeng Li
Mar 7, 2013·British Journal of Cancer·J ChenK Riabowol

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Related Papers

The International Journal of Biochemistry & Cell Biology
Wei GongK Riabowol
Molecular Biology and Evolution
Gordon H Y HeK Riabowol
Cellular and Molecular Life Sciences : CMLS
E I CamposG Li
Trends in Cell Biology
Xiaolan FengKarlT Riabowol
© 2021 Meta ULC. All rights reserved